Oxford Biomedica PLC Notice of Interim Results (2998K)
September 01 2021 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 2998K
Oxford Biomedica PLC
01 September 2021
Notice of Interim Results
London, UK - 1 September 2021: Oxford Biomedica plc (LSE:OXB), a
leading gene and cell therapy group, will be announcing its interim
results for the six months ended 30 June 2021 on Wednesday 22
September 2021.
A briefing for analysts will be held at 13:00 BST / 08:00 EST on
the day of the results at 85 Gresham Street, London EC2V 7NQ. There
will also be a live conference call with a Q&A session and live
webcast. The presentation and webcast details will be made
available on the Group's website at www.oxb.com. A replay of the
presentation will be made available shortly afterwards.
- Ends -
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Catherine Isted, Head of Corporate Development & IR
Sophia Bolhassan, Director of IR
Consilium Strategic Communications: T: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, cell
and gene therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders and liver diseases. The
Group has also entered into a number of partnerships, including
with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard
Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the
UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in
other potential gene and cell therapy products. Additionally the
group has signed a 3 year master supply and development agreement
with AstraZeneca for large-scale manufacturing of the adenoviral
based COVID-19 vaccine, AZD1222. Oxford Biomedica is based across
several locations in Oxfordshire, UK and employs more than 670
people. Further information is available at www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBIGDISXXDGBB
(END) Dow Jones Newswires
September 01, 2021 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024